Offering new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.
Executive Editor, Anna Radominska-Pandya, is currently accepting submissions on an array of drug metabolism research. Drug Metabolism Reviews provides critically needed reviews-- covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species.
Drug Metabolism Reviews is the official journal of ISSX, the International Society for the Study of Xenobiotics. Drug Metabolism Reviews ranks within the Top-Quartile in Pharmacology & Pharmacy, listed 30/261 and has a 2017 Impact Factor of 4.450*.
Review our Instructions for Authors site to ensure you have everything required to move through peer review, production and publication.
When you are ready to submit, please proceed via ScholarOne.
At the point of submission, you will be asked if there is a data set associated with the paper. If you reply yes, you will be asked to provide the DOI, pre-registered DOI, hyperlink, or other persistent identifier associated with the data set(s). If you have selected to provide a pre-registered DOI, please be prepared to share the reviewer URL associated with your data deposit, upon request by reviewers.
You can find more information about Taylor & Francis' Data Sharing Policy here.
- Executive Editor : Anna Radominska-Pandya, University of Arkansas for Medical Sciences, RadominskaAnna@uams.edu
Anna Radominska-Pandyareceived her Ph.D. from the Institute of Biochemistry and Biophysics at the Polish Academy of Sciences in Warsaw, Poland, and currently serves as a Professor in the Department of Biochemistry and Molecular Biology at UAMS in Little Rock, Arkansas.
Radominska-Pandya has published 175 papers in various peer-reviewed journals, and has received 12 R01 grants from the NIH, all related to the regulation and suppression of human UGTs and their role as anti-proliferative agents in cancer models, the interactions between UGTs and cannabinoid receptors, the delivery of UGT genes and drugs into cancer cells using nanomaterials, and the roles of UGTs in the biotransformation of drugs including resveratrols and drugs of abuse such as marijuana and synthetic cannabinoids.